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Abstract: Cell-secreted extracellular vesicles (EVs) have rapidly gained prominence as sources of
biomarkers for non-invasive biopsies, owing to their ubiquity across human biofluids and physiological
stability. There are many characterisation studies directed towards their protein, nucleic acid, lipid
and glycan content, but more recently the metabolomic analysis of EV content has also gained traction.
Several EV metabolite biomarker candidates have been identified across a range of diseases, including
liver disease and cancers of the prostate and pancreas. Beyond clinical applications, metabolomics has
also elucidated possible mechanisms of action underlying EV function, such as the arginase-mediated
relaxation of pulmonary arteries or the delivery of nutrients to tumours by vesicles. However,
whilst the value of EV metabolomics is clear, there are challenges inherent to working with these
entities—particularly in relation to sample production and preparation. The biomolecular composition
of EVs is known to change drastically depending on the isolation method used, and recent evidence
has demonstrated that changes in cell culture systems impact upon the metabolome of the resulting
EVs. This review aims to collect recent advances in the EV metabolomics field whilst also introducing
researchers interested in this area to practical pitfalls in applying metabolomics to EV studies.
Keywords: extracellular vesicles; exosomes; microvesicles; biomarkers; diagnostics; metabolic pathways
1. Introduction
Extracellular vesicles (EVs) are bioactive nanosized vesicles that are secreted by cells that mediate
intercellular communication through the transmission of functional biomolecules [1]. The term “EV”
encompasses multiple designations as determined by the biogenetic pathway in question or biophysical
characteristics of EVs [2]. Multivesicular-body-derived exosomes, for example, are created via the
inward budding of endosomes, with the resulting intraluminal vesicles released through fusion of the
endosome with the cell membrane. Elsewise, microvesicles directly bud off from the cell membrane and
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apoptotic bodies are the products of fragmented, dying cells. In addition to these three known classes of
EV, uncharacterised subtypes are likely to exist differing in their composition, ultrastructure, or size [3,4].
Since the discovery in the mid-2000s that EVs can transfer functional mRNA [5,6], there have been
increasing reports ascribing biological functions to EVs across an astounding range of contexts [1].
From developmental biology [7] and cardiovascular homeostasis [8] through to immunity [9] and
angiogenesis [10], there appears to be a role for EVs in every instance where biological material is
exchanged between cells. Correspondingly, the pathological dysregulation of these processes has also
been reported in cancer [11], neurodegeneration [12], obesity [13] and inflammatory diseases [14],
whilst the deployment of EVs by pathogens and microbiota is informing new paradigms on how we
interact with microorganisms [15–17].
Consisting essentially of a lipid bilayer, EVs also comprise a repertoire of proteins, glycans
and nucleic acids [1]. Some of these components are incorporated into vesicles during biogenesis
and are thought to be characteristic markers of EVs. Notable examples include CD9, CD63 and
CD81 of the tetraspanin protein family [18], high phosphatidylserine lipid content [19] and a
conserved glycosylation signature that has been described for mammalian EVs [20]. Depending
on the EV class in question, markers differ and guidelines from the Minimal information
for studies of extracellular vesicles (MISEV) working group recommend that transmembrane/
glycosylphosphatidylinositol-anchored(GPI-anchored) proteins and cytosolic proteins be analysed
in all bulk EV preparations in order to demonstrate the presence of EVs as well as non-EV structural
proteins for purity control [21]. However, the comparatively limited repertoire of molecular markers
cannot account for the diversity of functions ascribed to EVs, and online databases of EV omics studies
show a vast assortment of EV-associated compounds beyond these [22,23], signifying other means
of cargo packaging. Molecules may be trafficked directly to EVs through interactions with other
biomolecules or indirectly packaged during vesicle formation processes that encapsulate pockets
of cytosol [24]. Moreover, EV content is dynamic and shifts in response to perturbations in culture
conditions [25]. As such, EVs present as reflections of their cellular source, and the analysis of vesicle
content provides a nanoscopic window into the physiopathological state of said cells. There are
various examples of this concept in action with the identification of EV protein, lipid and nucleic acid
biomarkers for several diseases [26–28]. Additionally, EVs have been isolated from many human
biofluids [1], engendering a huge interest in the use of EVs for non-invasive liquid biopsies, and the
EV diagnostics sector is projected to reach a value of $100 million by 2021 [29]. In recent years, several
examples of metabolite biomarkers have been published [30,31] and EV metabolomics holds great
promise against this backdrop.
Metabolites are described as any biologically relevant molecule <2 kDa in size. This comprises a
large range of molecular species, from steroid hormones and lipids to the metabolic intermediates of
nutrient anabolism and the monomers of the major biopolymer classes. Considering that all cellular
processes involve metabolites in some form, assaying of metabolomes can provide information on
any dysregulation to these in a manner analogous to using EVs to study cellular status. For example,
UHPLC-MS analysis of urinary EVs from prostate cancer patients identified abnormal levels of the
steroid hormone dehydroepiandrosterone sulphate (DHEAS), suggesting this metabolite as a potential
marker of prostate cancer and also as a means of monitoring disease progression [32]. Beyond
providing disease biomarkers, metabolomics can also illuminate fundamental EV biology. It was
shown that cancer-derived fibroblasts can supply nutrients to cancer cells through EVs, which further
illuminates the mechanisms of the tumour niche [33]. Elsewise, EVs can also act as “metabolically
active machines”, as proven by the metabolomic analysis of serum samples mixed with hepatocyte
EVs. Therein, alterations in the levels of over 90 metabolites were detected, signifying the presence of
functional enzymes in EVs [34].
Whilst EVs present exciting opportunities for metabolomics researchers, there are intractable
practical difficulties inherent to working with EVs that must be considered from the outset of any
potential projects—difficulties that mainly relate to the different classes of EVs and the heterogeneity
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within these. For example, whilst isolation protocols can be targeted towards exosomes, the physical
and biomolecular properties of exosomes, microvesicles and apoptotic bodies overlap, meaning that
any exosome-targeted preparation likely also contains other EVs as contaminants and it is difficult
to assign vesicle designation with full certainty [21,35]. Even then, supposing totally pure exosome
purification, the stochastic nature of vesicle biogenesis gives each exosome a potentially unique
composition [2]. Any subsequent omics characterisation thus provides information for the bulk vesicle
population and ignores the possible contribution of relevant subpopulations. EV subpopulations
are also problematic for sample preparation, as multiple reports have shown how different isolation
methods generate different results during downstream characterization [36–39]. The matrix from which
EVs are obtained may partially dictate the isolation method, but the choice is further complicated by the
increasing number of commercial and published EV isolation methods. Finally, production methods
can also bias EV composition. This has been demonstrated for EVs from two prostate cancer cell
lines produced from either standard culture flatware or from bioreactors, with the metabolic signature
of these models shifting depending on the cell culture conditions [40]. Fortunately, despite these
complexities, the actual metabolomic analysis of a purified EV sample is straightforward and does not
present any sample-specific issues. In our hands, established techniques of metabolite extraction and
analysis have proven sufficient in generating sufficient data. A workflow of possible methodologies
for an EV metabolomics study is presented below (Figure 1).
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Figure 1. Key stages of the metabolomic analysis workflow for extracellular vesicle (EV) samples.
Methodologies of EV isolation can impact the etabolome and should be carefully considered
when comparing results from different studies. (CCM, cell conditioned medium; SEC, size
exclusion chromatography; GC, gas chromatography; HILIC, hydrophilic interaction chromatography;
RP, reversed-phase chromatography; Targeted analysis, detailed analysis of a predefined subset of the
metabolome; Non-targeted analysis, aximum metabolite coverage).
Her in, we aim to t e recent findings from EV metabolomics studies whi st placi g
an emphasis on the EV isolation and analy is method logies used to highlight the best practices.
The key studies so far and their salient information have been collected in Table 1 for asy reference.
Consid ration will also be given to the EV origins within studies, how the wider body of EV esearch
can inform future EV metabolomics studi s and whether a gold standard of EV sample p eparation
can ever be achieved. We will also cov r how metabolomics of other sample types has be n useful in
understanding the rol of EVs as metabolically active machine . It should be noted that there is crossover
between EV metabolomics and lipidomics, as th size of biologically relevant lipids categorises them
as metabolites. Since EV lipidomics is a more established field and has been excellently review d
elsewhere [41,42], we have focused on metabolites as small polar molecules involved in cellular
proc sses of metabolism.
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Table 1. Primary studies comprising metabolite analysis of EV samples.
Research Description Sample Type, Source EV Isolation Method Metabolomics Workflow Significant Metabolites
EVs secreted by cancerous
cells contain a suite of
metabolites that can be
received and metabolised
by cancer cells [33]
CD63+ EVs from
cancer-associated fibroblasts
Total exosome isolation
reagent
Methanol–chloroform
fractionation of EVs
followed by GC-MS or
UHPLC
Pyruvate, citrate, glutamine,
arginine, palmate, stearate
Plasma EVs from
adenocarcinoma patients
and PANC 1 cell culture
shown to possess broad
metabolomes [43]
CD63+/CD9+/TSG101+ EVs
from human plasma EVs
from PANC 1 cell culture
100,000× g
ultracentrifugation
Methanol–chloroform
fractionation of EVs
followed by
UHPLC-ESI-MS
Amino acids, substituted sugars
Metabolomics analysis of
urinary EVs revealed
potential prostate cancer
biomarkers [32]
EVs from urine of either
benign prostatic hyperplasia
or prostate cancer patients
100,000× g
ultracentrifugation
Methanol–chloroform
fractionation of EVs
followed by UHPLC-MS
Dehydroepiandrosterone sulphates,
other androsterone sulphate isomers
Identified vesicular
hexanal as a candidate
chemoattractant for
Anopheles gambiae vectors
of malaria [44]
EVs from patient-derived
red blood cell culture
110,000× g
ultracentrifugation
GC-MS with headspace
solid phase microextraction
of EV samples
Hexanal,
pentane2,2,4-trimethyl-pentane,
1,2,3-propanetriol diacetate
Comparative
metabolomics of EVs from
cells cultured with either
conventional flatware or
bioreactors revealed
significant differences [40]
Large and small
CD91+/CD9+/TSG101+ EVs
from PC-3 and VCaP cell
culture
20,000× g and 110,000× g
ultracentrifugation
Acetonitrile dissolution of
EVs followed by
UHPLC/Q-TOF-MS with
separation by either reverse
phase or hydrophilic
interaction
Amino acids, phosphatidylcholines,
phosphatidylethanolamines,
sphingomyelins
Metabolomics of urinary
and platelet-derived EVs
show enrichment of
specific molecules
compared to sample
matrices [45]
CD9+/CD63+/TSG101+ EVs
from urine of prostate
cancer patients and
platelet-derived EVs from
matched serum samples
100,000× g
ultracentrifugation for
urinary EVs (uEVs) and
110,000× g for
platelet-derived EVs
Acetonitrile dissolution of
EVs followed by
UHPLC-MS-MS
Spermidine, ornithine, carnitine
derivatives, nicotinamide adenine
dinucleotide, amino acids
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Table 1. Cont.
Research Description Sample Type, Source EV Isolation Method Metabolomics Workflow Significant Metabolites
Enrichment of certain
metabolite classes detected
in EVs after irradiation of
rhesus macaques [46]
Plasma-derived CD63+ EVs
from rhesus macaques
120,000× g
ultracentrifugation
Acetonitrile dissolution of
EVs followed by
UHPLC/Q-TOF-MS
Carnitines, sphingomyelins, amino
acids, 5-methycytosine, nonic acids
Outer membrane vesicles
from toxigenic and
nontoxigenic Bacteroides
fragilis spp. exhibit
different metabolomes [47]
Outer membrane vesicles
from Bacteroides fragilis spp.
culture
100,000× g
ultracentrifugation
Cold methanol extraction
of EV metabolites followed
by UHPLC-MS or GC-MS
Creatinine, creatine, glycerate-2P,
fumarate, malate, amino acids
Large EVs from
atherosclerotic plaques
present taurine
enrichment [48]
EVs from human carotid
atherosclerotic plaques
20,500× g
ultracentrifugation
Proton nuclear magnetic
resonance spectroscopy
Taurine, lactate,
glycerophosphocholine
Change in serum EV
metabolome after
chemotherapy [49]
Serum exosomes from
pancreatic cancer patients
before and after
chemotherapy
100,000× g
ultracentrifugation
50% methanol and
freeze–thaw cycle for
extraction followed by
LC-Q-TOF-MS
Alanyl-histidine,
6-dimethylaminopurine,
leucyl-proline, and methionine
sulfoxide
EVs secreted by
mesenchymal stem cells
contain a suite of
metabolites that can be
received and metabolised
by other cells [50]
EVs derived from
mesenchymal stem cell
culture
Ultrafiltration followed by
110,000× g
ultracentrifugation
Methanol extraction
followed by CE-UV and
HPLC-MS/MS
Diacylglycerols, sphingomyelins,
lactate, glutamate
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2. Metabolomics of Patient-Derived EVs
Considering the potential of EVs for non-invasive liquid biopsies, the identification of robust
metabolite biomarkers in EVs is a key goal. Such studies necessitate the use of EVs extracted from
clinical samples for greater impact and translation. An instructive example comes from a metabolomics
study of urinary EVs (uEVs) in the context of prostate cancer [32]. Therein, 50 mL of urine from
patients with either prostate cancer (PCa) or benign prostatic hyperplasia (BPH) was sterile filtered
and frozen at −80 ◦C immediately following collection. Subsequent EV isolation from the urine was
performed by differential ultracentrifugation—first centrifuged for 30 min at 10,000 × g to remove the
majority of larger vesicles before pelleting of small uEVs at 100,000 × g for 75 min. Processing of all
uEV samples was performed by fractionation with methanol and chloroform into different phases
of metabolites for UHPLC-MS analysis. Through this methodology, researchers detected differential
metabolite content in the patient-derived uEVs and highlighted 76 of these as statistically significantly
different between the PBH and PCa samples. Crucially, 3beta-hydroxyandors-5-en-17-one-3-sulphate
(dehydroepiandrosterone sulphate, DHEAS) was raised in the uEVs from PCa patients compared to
BHP patients, potentially enabling clinicians to distinguish between these often-confused diagnoses.
The study continued with bioinformatics analysis of published gene expression data to identify a
decrease in steroid sulphatase in the PCa samples, correlating with disease progression. DHEAS is a
substrate for this enzyme, and its loss in advanced PCa suggests that DHEAS accumulation could also be
used to stratify patients according to disease progression. The question remains as to whether a baseline
DHEAS level could be established to show meaningful DHEAS deviations as a biomarker for initial
PCa identification. Furthermore, the pathological relevance of EV-associated DHEAS is potentially
interesting. No more than 10% of DHEAS is produced from the gonads of healthy males, instead
primarily originating from the adrenal glands [51]. It is possible that the dysregulation of the steroid
sulphatase gene in the cancer context could lead to more constitutive DHEAS signalling, exacerbating
prostate tumour severity. In all, this study highlights how a combinatorial approach of metabolomics in
combination with other methods can add value to diagnostics and provide new insights to disease.
Another proof-of-concept study for extracting EV metabolite biomarkers from biofluids was
established with the plasma of endometrial adenocarcinoma (EAC) patients [43]. Plasma was
obtained from 10 mL samples of blood from both EAC patients and control subjects before storage at
−80 ◦C. EVs were again isolated through ultracentrifugation, although with a first centrifugation at
16,500× g and the second at 100,000× g for 120 min. Methanol–chloroform fractionation was employed
to release metabolites and UPLC-ESI-MS was used for data acquisition. Due to inconsistencies
between the data and metabolite databases, accurate mass-based identification of the detected
metabolites could not be performed, beyond a few amino acids and substituted sugars. However,
principal component analysis of metabolites revealed a clear separation between the plasma of healthy
control subjects and those of the cancer patients, indicating the potential for even incomplete EV
metabolomics in disease identification. Both these studies used ultracentrifugation for EV purification,
albeit with some differences to their protocols. Previously described as the “gold standard” of EV
isolation [52], this approach is straightforward and well suited to generating proof-of-concept data.
However, ultracentrifugation is not appropriate for clinical diagnostics due to specific equipment
requirements [53]. Other isolation methods are also available, such as size exclusion chromatography,
immunoaffinity and precipitation-based methods. Each has their own advantages and drawbacks
in terms of selectivity and yield, and these have been described with detail in a recent review [54].
In the case of urinary EVs, different clinically relevant EV purification methods were compared against
ultracentrifugation, selected on the basis of minimal equipment requirement [37]. Said methodologies
comprised several commercially available EV isolation kits working on precipitation principals and a
method of lectin-based EV capture [55]. The protein and RNA composition of purified EVs was found
to be heavily influenced by the isolation method, with EV markers CD9 and CD63 nearly absent in some
purified samples. Inter-donor samples were also found to vary wildly in marker content when the same
isolation method was used, highlighting the difficulty of establishing biomarker baselines. Considering
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this evidence, it is essential that this comparative approach is extended to EV metabolomics in order to
ascertain whether there are similar method-dependent effects on EV metabolite content.
3. Metabolomics of EVs from Cell Culture
Whilst extracting EVs directly from biofluids has direct clinical prospects, there are advantages
to culturing patient-derived cells in vitro for understanding disease. Specifically, the EVs of
cancer-associated fibroblasts have been examined and a potential role found for their EVs in modulating
the metabolism of cells from the cancerous PC3 line [33]. This study took fibroblasts originally isolated
from cancer patient tumours and cultured these in either normal conditions or in media supplemented
with various 13C-labeled molecules including glucose, pyruvate, and lysine. Therein, the commercial
Total Exosome Isolation Reagent from Thermo Fisher was used to isolate EVs directly from the cell
culture media and the study employed complementary metabolomics approaches to characterise the
cargo of these EVs. GC-MS (gas chromatography) highlighted a high vesicular content of the nutrients
pyruvate and citrate, whilst UHPLC identified a number of essential amino acids, with glutamine
and arginine particularly enriched. Downstream functional studies proved that these metabolites,
which were supplied by the EVs produced in the presence of 13C-labeled molecules, could be taken up
and utilised by the receiving PC3 cells. The EVs were found to be within the size range for exosomes
(30–100nm) according to nanoparticle tracking analysis, and were positive for CD63.
Beyond considerations in EV sample preparation, some forethought must also be given to the
types of molecules one wishes to analyse. No single method is able to cover the entire spectrum of the
metabolome. This is well exemplified with the EVs from red blood cells in relation to malaria and the
transmission of the Plasmodium falciparum parasite by Anopheles spp. [44]. Understanding the processes
of mosquito attraction to humans requires the study of volatile organic compounds as the transmitters
of human scent over distances. Red blood cells from infected and non-infected volunteers were
cultured ex vivo and the resulting conditioned media subjected to differential ultracentrifugation for
30 min at 15,000× g and 110,000× g for 70 min for EV purification. Metabolite extraction was performed
concurrently with GC-MS using the headspace solid phase microextraction (HS-SPME) method. Briefly,
EV samples were sealed in GC vials in the presence of a divinylbenzene/carboxen/polydimethylsiloxane
fibre for 12 h at 37 ◦C before injection to the mass spectrometer. The HS-SPME GC-MS method
was chosen to select for volatile organic compounds, and 18 of such were identified from EVs,
of which diacetin was found to be increased in the EVs derived from infected red blood cells.
The ultracentrifugation supernatants were also analysed, and in turn, hexanal was found solely in
infected supernatants. Together, these are possible mosquito chemoattractants upregulated after
infection with P. falciparum. which were discovered by metabolomics.
Importantly, the method of cell culture can also impact upon the metabolite composition of
EVs, and may need to be considered when results of different studies are compared. This issue was
highlighted by a recent article comparing the EVs of two prostate cancer cell lines produced either in
conventional cell culture flatware or bioreactor culture [40]. Large and small EVs from either 20,000× g
or 110,000× g ultracentrifugation steps were collected from both the VCaP and PC-3 lines cultured
in either condition. EV samples were disassembled in acetonitrile and subjected to LC-ESI-MS with
separation with either reversed-phase or hydrophilic columns. EVs were found to possess broadly
similar physical characteristics regardless of the culture method, but significantly different levels of
459 metabolites were seen across both cell lines. Indeed, some molecules were unique to bioreactor or
flatware culture, indicating different pathways of metabolic activity in the producing cells altering the
identity of the resulting EVs. Whilst illustrative of the issues in EV sample generation, the implications
of this work go beyond the differential metabolite results. There is significant interest in translating
EVs as therapeutics to the clinic which will necessitate production scale-up to bioreactor levels from
the flatware of standard research laboratories. Functional metabolite cargoes have already been proven
in the case of cancer nutrient supply [33] and depending on the treatment modality of the candidate
therapy, their efficacy may be impacted upon changes in metabolite content. This study should serve as
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a warning to therapy developers to characterise their products at all levels during process development.
Moreover, understanding how the production conditions influence the metabolite content of the EVs
may highlight novel methods to modulate their innate content.
4. Enrichment of Metabolites in EVs vs. EV Source
Metabolite enrichment in exosomes can sometimes facilitate the detection of certain low-abundance
disease markers which are below the detection limit using the sample matrix alone. However, careful
quantification of metabolite concentrations in both exosomes and matrices is required to validate
enrichment. Failure to actively prove enrichment can have varied consequences. In the best-case
scenario, it may be that a raw matrix shows biomarkers at sufficient concentrations to enable diagnosis,
forgoing the need for advanced EV-targeted methods. However, it is more likely that a putative EV
biomarker is not significantly enriched when compared to the biofluid, invalidating EV-associated
biomarker application. More concerning outcomes are also possible. For the EV field, this is best
exemplified by the contamination of EV preparations by exogenous nucleic acids from foetal bovine
serum (FBS) media additives in a number of high-profile studies [56,57]. Prior to these cases, it was
assumed that the ultracentrifugation-mediated EV-depletion of FBS was sufficient to remove excipient
contaminants. Now, the findings of many publications have been called into question—a warning to
all not to take EV sample preparation pitfalls lightly. Similarly, the recent identification of “exomeres”
as distinct, functional nanoparticulate entities that can copurify with EV preparations may also present
issues in future [58,59].
Therefore, it is important to always analyse the EV source matrix alongside the processed
EV sample (e.g., the cell culture media direct from the bottle and without exposure to cells).
For ultracentrifugation-based EV studies, retention and analysis of the supernatant can also suffice
to determine any carryover from the cell culture media or biofluids, depending on the project.
Alternatively, commercial isolation kits typically function by precipitation methods, and the work
and supernatants from these should also be tested. A practical example comes from a comparative
study on uEVs and platelet-derived EVs (pEVs) [45]. Therein, the metabolite content of uEVs purified
by ultracentrifugation was measured by UHPLC-MS and compared to that of the originating urine
filtrate, alongside pEVs compared with the parental platelets. In both systems, there was a high degree
of metabolite overlap between the EVs and the source material, but certain classes of metabolites
were enriched in the EV samples, suggesting an active recruitment of these molecules into the EVs.
The largest changes in uEVs were observed for spermidine, ornithine and nicotinamide adenine
dinucleotide (NAD), each enriched >600-fold compared to urine. Nucleotide and amino acid pathway
metabolites were also significantly enriched. On the other hand, pEVs contained 11 unique molecules
compared to the source platelets which only had one, but the enrichments were less dramatic for
common metabolites. For example, a 250-fold upregulation of adenosine was the largest of these,
followed by carnitine and various carnitine derivatives with 10- to 50-fold enrichments. Finally,
inter-sample comparison of uEVs showed larger differences between the prostate cancer patients
and the healthy controls than in the comparison between urine samples. Further comparison of the
metabolite profiles from uEVs against pEVs revealed some common metabolites but also a broad range
of unique molecules, highlighting the point that specific biofluids will be better starting points for
specific diseases. Together, these data support the isolation of EVs as carriers of metabolites to identify
otherwise missable biomarkers.
5. Metabolomics of Non-EV Samples
It is interesting to note how the metabolomics toolkit can be applied to questions of EV biology
without direct EV analysis. This approach is well exemplified by complementary studies proving EVs
as metabolically active entities by assaying the blood metabolome after incubation with EVs from
rat primary hepatocyte culture [34,60]. Therein, small volumes of rat serum were incubated for 1 h
with the EVs collected from 110,000× g ultracentrifugation and the metabolites then extracted through
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methanol–chloroform fractionation for UHPLC-MS analysis. In both studies, blood metabolome
shifts were observed after incubation with EVs, specifically molecules of the arginine biosynthesis
pathway, demonstrating that EVs are capable of actively modulating metabolites with their enzymatic
content. This provides a novel concept of EVs as metabolic machines. These findings were further
developed for arginase-positive EVs in an assay of pulmonary endothelial induction [34], based on the
action of arginine as a nitric oxide precursor. The EVs inhibited the relaxation of isolated pulmonary
arteries, providing direct proof that EVs can effect physiological changes through metabolome
alteration. In related stories of active enzyme content, the presence of functional asparaginase,
α2-6-sialyltransferase 1 (ST6Gal-I) and extracellular nicotinamide phosphoribosyltransferase (eNAMPT)
have all been demonstrated in EVs [59,61,62]. eNAMPT is of particular note for its role in nicotinamide
adenine dinucleotide metabolism, heavily associated with mechanisms of aging. Given the rapid rate
of publication for these recent discoveries, it is exceedingly likely that metabolomics will reveal more
such metabolically active EVs in future [63].
6. Conclusions and Future Directions
EV metabolomics is a nascent field but one with great potential, as evidenced by the interesting and
varied findings presented in this review. The issues of EV sample preparation will always be inherent
but are not insurmountable, as long as methods are clearly reported alongside sufficient controls and a
suite of vesicle characterisation tests. That said, understanding in the field is continually evolving, as
exemplified by the issues of contaminating nucleic acids from FBS media [57] or the disputed use of
previously accepted EV markers [64]. To better facilitate inter-study comparison now and in posterity,
full reporting is essential. It is worth consulting the MISEV and EV-TRACK (Transparent Reporting
and Centralizing Knowledge in Extracellular Vesicle Research) guidelines in this regard [21,65].
These initiatives detail the minimal reporting requirements that should be included in a reproducible,
quality study. However, there are no specific instructions for metabolomics reporting as yet, and
these also need to be established or perhaps adopted from previous metabolomics standardisation
initiatives [66]. EVpedia has allowances for metabolomics datasets [22], and we encourage researchers
to fully utilise this resource and upload any findings to facilitate future bioinformatics analyses.
There is a great interest in using EVs for diagnostic purposes. However, the validation of
biomarkers of any sort is a lengthy pursuit with many regulatory hurdles where failure is possible [67].
In these early days of EV metabolomics, it is worth pre-empting these challenges as much as possible
through careful methodological planning. In this regard, it may be necessary to further standardise
working practices. For example, the amount of EVs used for metabolomics varies across studies.
One such work gives a vesicle count of 1010 particles for their experiments [45], and a similar number
should perhaps be adopted by the field to ensure consistency between datasets. Moreover, the vast
majority of studies presented here have used ultracentrifugation and the supremacy of this method as
the “gold standard” has been challenged in recent years. With the ever-increasing amount of published
methods, it is unlikely that a single best method will emerge and instead the choice of isolation method
will be determined by the end application. Toward this end, we recommend that clinically relevant
methods be adopted as soon as possible for biomarker studies [37,53]. Finally, the practical challenge
of detecting biomarker shifts in a given patient is also worth considering. These may be too subtle to
detect without previous patient sample data, necessitating a program of routine EV metabolite analysis
that is unfeasible in practice. Future efforts should be made to establish a baseline EV metabolome for
healthy humans from which deviations can be inferred.
EV metabolomics is useful for understanding certain EV functions, but questions remain regarding
fundamental EV biology. For example, the investigation of EV subpopulation metabolomes has not been
described, but may prove valuable to this area of high interest. This is a challenging task to undertake
due the already low yield of total EV samples, particularly with the highly selective purification
methods of marker-targeted affinity isolation or ultracentrifugation in combination with further
chromatography steps [21]. Nonetheless, inevitable improvements in the sensitivity of metabolomics,
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such as nanoflow liquid chromatography-nanoelectrospray ionization (nLC-nESI) [68], along with
more refined purification techniques, will hopefully enable these questions to be answered.
Despite the encouraging results collected herein, the full power of EV metabolomics is yet to
be realized. We have used examples from biological pathologies, but the metabolome changes from
physical stimuli can also be detected—as in the case of primates exposed to damaging radiation [46],
which could potentially prove useful in monitoring exposure levels of radiotherapy technicians.
Moreover, the metabolomics of pathogen EVs may further the understanding of infection from bacterial
species [47]. Elsewise, the studies with patient-derived EVs presented here have focused on cancer,
but metabolite biomarkers have already been suggested in neurodegeneration and even psychiatric
disorders [69]. Such pathologies present different challenges in identifying valid patient–control
cohorts but there is no reason that EV-targeted metabolomics may not prove useful in enriching the
scanty biomarkers in these contexts. We hope that having read this review, metabolomics and EV
researchers are encouraged to seek EV metabolite-related projects and contribute materially to this
promising field.
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